CancerCell is a development stage company within the Leonhardt’s Launchpads innovation accelerator, operated by Cal-X Stars Business Accelerator, Inc. We are developing the world’s first multi-modality bioelectric therapy protocol for cancer tumor treatment and organ recovery.
Discover our background, mission, and the world-class research driving our next-generation medical technology.
CancerCell is a development stage startup company within the Leonhardt’s Launchpads innovation accelerator, operated by Cal-X Stars Business Accelerator, Inc. focused on bioelectric signals to stop tumor growth by halting cell division and starving blood supply to the tumor.
“It’s not enough using only one technology to fight cancer. You need to combine as many therapies as possible.” – Dr Andrea Pavesi at the Singapore-MIT Alliance for Research and Technology
CancerCell is developing a multi-stage bioelectric therapy for eradicating cancer tumors and regenerating organs back to full health after cancer. Our comprehensive business and clinical model includes:
Discover the science and innovation driving our advanced solutions, designed to deliver safe, effective, and transformative results.
CancerCell is the world’s first patented protocol that reads cancer tumors in real-time to deliver customized bioelectric therapy. Our “Read and React” approach ensures that tumors are eradicated and damaged organs are regenerated back to full health.
CancerCell is the World’s first multi-modality bioelectric therapy protocol for cancer tumor treatment. Our proprietary treatment follows these precise steps:
Based on the real-time read, customized personalized bioelectric signals are delivered to:
If the cancer tumor is eradicated (or growth subsided), the bioelectric stimulator is designed to do the following afterwards to recover the organ back to full health:
Don’t see your question? Reach out and our clinical team will respond personally.
Read a the bioelectric signals of a cancer tumor and then custom deliver precise signals to…
The bioelectric signals are designed to communicate with the cell membranes and DNA within their cell nucleus to control protein expressions and reprogramming. This often is via controlling membrane potential and cell pore opening and closings as well as micro RNA expressions.
Novocure sponsored a pilot study of electrical fields to jam the communication ability of brain tumor cells and had successful results. This lead to FDA approval for their product for the limited to only most aggressive types of brain cancer.
Pulsed Biosciences, Inc. a California based company sponsored some small pilot studies utilizing pulsed electro magnetic fields to slow the growth of skin cancer tumors and reported successful results.
We are just starting now our very first small animal studies. From this stage forward to clinical trials normally take 5 years. We hope to reduce this time period but have no assurances we will be able to do that. We will likely start clinical trials outside of the USA before the USA as is the common practice in our field.
Want to learn more? Browse our clinical resources and scientific publications on our comprehensive suite of targeted treatments.
Access our official treatment protocols and comprehensive list of issued patents that form the foundation of our bioelectric cancer therapy.
Explore peer-reviewed articles and clinical studies detailing the effectiveness of electrical stimulation in oncology and advanced tumor treating fields.
Independent research validating the bioelectric code and targeted electromagnetic therapies for reprogramming cancer cells and improving patient survival rates.
Want to learn more? Browse our clinical resources and scientific publications on our latest updates and insights.
CAUTION Disclaimer and Warning: Products described on this web site are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. Any statement or phrases implying efficacy or safety in any form are considered modified by “intended to” or “designed to”. Investigational use only in countries where investigation is permitted by law and proper filings have been made and appropriate regulatory clearances have been granted. Any use of the product(s) must be in an authorized clinical study with institutional review board (ethics committee) approval and proper patient consent procedures followed. For other countries product is only available for laboratory investigation by credentialed institutions and investigators with proper clearances with a research agreement in place with a study sponsor. NOT AVAILABLE FOR SALE.
CancerCell combines real-time tumor sensing with patented bioelectric signals to jam cancer communications, starve blood supply, and trigger natural immune responses. Our multi-modality protocol is designed to eradicate tumors and regenerate damaged organs back to full health.
